Serving as a professor at Johns Hopkins for over a decade, Dr. Le recently decided to step out of her comfort zone and start her own company in Baltimore’s Inner Harbor, Gigantest, which provides next-level metabolomics services for scientists and physicians at leading institutions around the world.
Curing HIV is an expensive endeavor, and under Sabrina Campbell’s watchful eye, an innovative service is funding the gene therapy trial that may lead to the end of the HIV epidemic. At the beginning of the COVID-19 pandemic, there was a shortage of PCR testing, which prompted American Gene Technologies® to open its own laboratory to bridge supply and demand. Every dollar of profit from the COVID-19 PCR tests performed in the clinical laboratory pays for the HIV Cure Program’s Phase 1 human trial. With such a critical responsibility, the clinical laboratory must operate uninterrupted, which is why we’re thrilled to highlight Sabrina Campbell, the lab manager who’s aiding a potential HIV cure with COVID-19 testing revenue.
Novavax Names John C. Jacobs as New President & Chief Executive Officer
Jan 9, 2023
Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity
Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline development
GAITHERSBURG, Md., Jan. 9, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors. The transition will be effective as of January 23, 2023. Mr. Erck will serve as an advisor to the Company for the next fifteen months to enable a smooth transition.
“As we prepare for Stan’s retirement, the Board reflects on the incredible legacy he leaves behind,” said James F. Young, PhD, Chairman of the Board of Directors. “Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic. This foundation puts Novavax in a strong position to execute on its long-term strategy, and we look…
McBee, Moore & Vanik IP welcomes its newest team members, Tiana Glascoe and Hannah Bernstein.
Halperin brings over 35 years of pharmaceutical industry experience to the newly created role. Prior to joining Conexus, he held several senior practice leadership roles at Accenture, Tata Consulting Services, etc., as well as in the Technology function at companies such as Johnson & Johnson, Merck, and Otsuka Pharmaceuticals. Most recently, he established and led the internal IT function for a bio-pharmaceutical start-up where he was responsible for implementing a new technology infrastructure and application portfolio to support the Commercial, R&D, and Corporate Support functions within the company.
Josh Green is a mentor and entrepreneur whose career has primarily focused on business and organizational development. He is currently the Director of the Innovation Commercialization Assistance Program (ICAP) – a program of George Mason University and the Virginia SBDC. ICAP works with early-stage technology and innovation-driven companies to validate their market and continues to support them as they seek investment and scale their ventures. For 15 years, he has advised private companies and nonprofit organizations across the United States in a wide array of industries.
Rockville, Maryland’s American Gene Technologies (AGT™) HIV cure program has been making remarkable progress in its mission to bring a single-dose cure to people living with HIV. That mission is steadily advancing through a successful Phase 1 human clinical trial. The company hopes to begin its Phase 2 study during 2023; this could yield very compelling data towards a functional cure, occurring perhaps as early as the first half of 2024.
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, announces Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada.
We at BioBuzz have always strived to center ourselves around the individuals who have worked to push the biohealth sphere to new heights. Our “5 Questions With…” series embodies this effort as we have highlighted professionals at all levels, from early career to the C-suite, from scientists to business developers to managers and directors. Regardless of position or title, the many individuals highlighted in 2022 are all changemakers in their own right and we greatly appreciate their work and contribution to this series.
During the pandemic, I think many people went through a lot of self-reflection—including myself! Through personal health experiences, and also participating in a COVID-19 vaccine trial, I realized how important to me it was to serve a mission related to healthcare and science. It’s a field that ultimately saves lives – and with that I landed here at MilliporeSigma, a biotechnology company at Rockville, MD. I am currently the Head of People Strategy Execution for our Rockville site, which in short, I like to describe as “people harmony.” My work includes recruiting, community partnerships, employee engagement, DE&I, and leadership development.